The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.

Frank Kung Biography and Net Worth

Director of Amyris

Dr. Frank F. C. Kung Ph.D. serves as Independent Director of the Company. Dr. Kung is a founding member of Vivo Capital LLC (“Vivo”), a healthcare focused investment firm founded in 1996 in Palo Alto, California, whose fund under management is an owner of greater than five percent of the Company’s outstanding common stock. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1983, he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley.

What is Frank Kung's net worth?: The estimated net worth of Frank Kung is at least $0.00 as of September 21st, 2022. Dr. Kung owns 80,000 shares of Amyris stock worth more than $0 as of November 2nd. This net worth approximation does not reflect any other investments that Dr. Kung may own. Learn More about Frank Kung's net worth.
How do I contact Frank Kung?: The corporate mailing address for Dr. Kung and other Amyris executives is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. Amyris can also be reached via phone at (510) 450-0761 and via email at [email protected]. Learn More on Frank Kung's contact information.
Has Frank Kung been buying or selling shares of Amyris?: Frank Kung has not been actively trading shares of Amyris over the course of the past ninety days. Most recently, Frank Kung sold 200,000 shares of the business's stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $3.50, for a transaction totalling $700,000.00. Following the completion of the sale, the director now directly owns 80,000 shares of the company's stock, valued at $280,000. Learn More on Frank Kung's trading history.
Who are Amyris' active insiders?: Amyris' insider roster includes Eduardo Alvarez (COO), Anthony Hughes (CAO), Nicole Kelsey (Insider), Hermanus Kieftenbeld (CFO), Frank Kung (Director), James McCann (Director), and John Melo (CEO). Learn More on Amyris' active insiders.

Frank Kung Insider Trading History at Amyris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/21/2022	Sell	200,000	$3.50	$700,000.00	80,000
9/19/2022	Sell	1,080,676	$3.80	$4,106,568.80	109,460
9/15/2022	Sell	1,385,000	$4.20	$5,817,000.00	458,591
4/13/2021	Sell	4,678,363	$14.96	$69,988,310.48	2,266
6/5/2020	Buy	3,689,225	$3.00	$11,067,675.00	2,932
4/29/2019	Buy	913,529	$4.76	$4,348,398.04	3,599
8/20/2018	Sell	3,924,884	$6.22	$24,412,778.48	4,266

Frank Kung Buying and Selling Activity at Amyris

Amyris Company Overview

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Today's Range

Now: N/A

50 Day Range

MA: $0.54

$0.05

$1.17

2 Week Range

Now: N/A

Volume

46,746,000 shs

Average Volume

12,593,118 shs

Market Capitalization

$18.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Musk warns humanity: “Obsolete”

From The Freeport Society | Ad

Go here to see why.